Diltiazem Loading Dose for Atrial Fibrillation with Rapid Ventricular Response
The recommended loading dose of diltiazem for AF with RVR is 0.25 mg/kg actual body weight administered intravenously over 2 minutes (approximately 20 mg for an average-sized patient), with a second dose of 0.35 mg/kg over 2 minutes (approximately 25 mg) given after 15 minutes if the initial response is inadequate. 1
Initial Bolus Dosing
The FDA-approved dosing strategy is straightforward 1:
First dose: 0.25 mg/kg actual body weight IV over 2 minutes
- For average patients, this equals approximately 20 mg
- Patients with low body weight should be dosed on mg/kg basis
Second dose (if needed after 15 minutes): 0.35 mg/kg actual body weight IV over 2 minutes
- For average patients, this equals approximately 25 mg
- Some patients may respond to a lower initial dose of 0.15 mg/kg, though experience is limited and duration of action may be shorter
Both major guidelines 2, 3 support diltiazem as first-line therapy for rate control in AF with RVR, particularly when left ventricular ejection fraction is >40%.
Continuous Infusion Following Bolus
After successful bolus administration and heart rate reduction 1:
- Initial infusion rate: 10 mg/h
- Some patients maintain response at 5 mg/h
- May increase in 5 mg/h increments up to 15 mg/h maximum
- Duration should not exceed 24 hours
- Infusion rates >15 mg/h are not recommended due to dose-dependent, non-linear pharmacokinetics
Important Clinical Considerations
Dosing in obesity: Recent evidence shows obese patients often receive lower actual-body-weight-based doses (0.16 mg/kg vs 0.21 mg/kg in non-obese patients) 4. However, ideal body weight dosing may better align with guideline targets and appears safe. Higher initial doses increase likelihood of early rate control without increasing adverse events 4.
Lower-dose alternative: Evidence suggests doses ≤0.2 mg/kg may be as effective as standard dosing (>0.2-0.3 mg/kg) for rate control while significantly reducing hypotension risk (18% vs 35%, adjusted OR 0.39) 5. This may be particularly relevant in hemodynamically sensitive patients.
Heart failure with reduced ejection fraction: Exercise caution—diltiazem should be avoided in HFrEF per guidelines 2. In patients with EF <50% who received diltiazem and required hospital admission, worsening heart failure occurred in 17% versus 4.8% in those with preserved EF 6.
Expected Efficacy and Timing
- Rate control achieved in 65-69% of patients at 30 minutes 4
- 86-87% achieve control by 3 hours
- Over 93% by 6 hours
- Maximal hemodynamic effects typically occur within 2-5 minutes of injection 1
Safety Profile
Overall adverse event rates are approximately 19% with diltiazem 7. The most common adverse events include:
- Hypotension: 18-42% depending on dose 5
- Bradycardia: Less common, no significant difference versus metoprolol 7
Critical contraindications 2:
- Heart failure with reduced ejection fraction
- Severe hypotension
- Sick sinus syndrome without pacemaker
- Second or third-degree AV block without pacemaker
The protocol adherence matters significantly—when diltiazem is given according to strict protocols, adverse event rates drop to 8% versus 18% when given outside protocol parameters 8.